FAQs

Yes. The Autoimmune Neuromuscular Drug Development Summit is uniquely designed as an indication‑focused and mechanism‑driven forum, dedicated specifically to autoimmune neuromuscular and peripheral nerve disorders such as Myasthenia Gravis (MG), CIDP, GBS and MMN.

Unlike broader neurology or immunology events, this summit goes beyond high‑level discussion to focus on the core scientific and translational challenges impacting drug development, including disease biology, patient stratification and clinical strategy. By bringing together biopharma leaders working on similar indications, it enables more in‑depth, relevant and actionable conversations.

The Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit focuses on autoimmune neuromuscular and peripheral nerve disorders, with particular emphasis on:

• Myasthenia Gravis (MG)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain‑Barré Syndrome (GBS)
• Multifocal Motor Neuropathy (MMN)

The event is specifically designed to address the shared and unique biological, translational and clinical challenges across these indications, helping drug developers navigate complexity and heterogeneity in patient populations.

Yes. Interactive workshops precede the main program, and are designed to provide deeper exploration of key challenges in autoimmune neuromuscular drug development:

Workshop A: Defining Heterogeneous Disease Biology to Unlock Precision Therapies with UCB and argenx:

• Mechanistic differences across AChR+, MuSK+ and seronegative MG
• Immunologic uncertainty in CIDP and MMN
• Why heterogeneity is limiting biomarker validation and patient stratification
• Strategies to biologically stratify patients earlier in development

Workshop B: Bridging In Vitro & In Vivo Preclinical Gaps to Improve Clinical Translation with Biohaven, Cartesian Therapeutics, and Alnylam Pharmaceuticals:

• Limitations of current CIDP and GBS models
• When bypassing animal models may be justified
• Embedding clinically relevant biomarkers into preclinical systems
• Defining truly translatable efficacy signals

These workshops are designed to complement the main conference by providing hands‑on, solution‑focused learning.

Discover full workshop details in the full event guide.

Yes. The Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit brings together a select group of biopharma leaders working specifically on autoimmune neuromuscular and peripheral nerve disorders such as MG, CIDP, GBS and MMN, ensuring that every discussion, presentation and networking opportunity is directly relevant to your area of interest.

Topics concentrate on:

• Indication‑specific challenges in autoimmune neuromuscular diseases
• Key mechanisms including FcRn, complement and B‑cell targeting
• Translational and clinical drug development strategy

This meeting enables deeper technical insight, more productive discussions and stronger connections with peers facing the same challenges, resulting in a more time‑efficient, collaborative and high‑impact experience compared to broader, less specialized meetings.

Yes. A central focus of the Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit is addressing translational bottlenecks that limit clinical success.

Discussions explore:

• The gap between preclinical models and human disease biology
• Challenges in validating predictive biomarkers
• Difficulties in translating immune modulation into clinical outcomes
• How to improve decision‑making earlier in the drug development pipeline

The event is designed to help attendees de‑risk development and improve the likelihood of clinical success in complex autoimmune conditions.

Yes. The summit highlights next‑generation therapeutic strategies shaping the autoimmune neuromuscular space, including:

• FcRn inhibitors
• Complement‑targeting therapies
• B‑cell‑targeted approaches
• Novel immunomodulatory mechanisms

These rapidly advancing modalities are transforming the treatment landscape and creating new opportunities for differentiation and innovation in drug development.

Yes. Biomarker development is a key topic across the Autoimmune Neuromuscular & Nerve Disorders Conference, with a strong focus on:

• Autoantibody measurement and validation
• Biomarkers for disease activity and progression
• Tools for improving patient stratification
• Integration of biomarkers into clinical trial design

Given the heterogeneity of autoimmune neuromuscular diseases, improving biomarker strategies is critical to enabling precision medicine and more effective clinical outcomes.